FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

Jun 12, 2018

|

NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market on Tuesday that the US Food and Drug Administration has approved the Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Keytruda (pembrolizumab) for cervical cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

To read the full story....

Breaking News

Illumina to Acquire Grail for $8B in Cash and Stock

Scanwell Health Receives $1.6M NIH Grant to Develop At-Home Test for Chronic Kidney Disease

Yourgene Inks US Distribution Deal for Chemotoxicity Assay, Other Tests

Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Illumina to Acquire Grail for $8B in Cash and Stock

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships